Antibody engineering and its applications in tumor targeting and intracellular immunization

FEMS Microbiology Letters

Volumn 189, Issue 1, 2000, Pages 1-8

  Chames, Patrick ^a   Baty, Daniel ^b  

^a MAASTRICHT UNIVERSITY   (Netherlands)

^b CNRS   (France)

Author keywords

Antibody fragment; Engineering; Escherichia coli; Intrabody; Phage display

Indexed keywords

CANCER ANTIBODY; HYBRID PROTEIN; IMMUNOGLOBULIN F(AB) FRAGMENT; RECOMBINANT ANTIBODY; VIRUS VECTOR;

BACTERIOPHAGE; DRUG DESIGN; DRUG RESEARCH; DRUG TARGETING; ESCHERICHIA COLI; GENETIC ENGINEERING; PHAGE DISPLAY; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; STRUCTURE ACTIVITY RELATION; TECHNIQUE;

ESCHERICHIA COLI;

EID: 0034256057     PISSN: 03781097     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0378-1097(00)00251-2     Document Type: Short Survey

References (45)

1. Erlich, P. (1957) In: Immunology and Cancer Research, Vol. 2 (Himmelweit, F., Ed.), Permagon Press, Oxford.
2. Kohler G., Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature. 256:1975;495-497.
3. Skerra A., Pluckthun A. Assembly of a functional immunoglobulin Fv fragment in Escherichia coli. Science. 240:1988;1038-1041.
4. Better M., Chang C.P., Robinson R.R., Horwitz A.H. Escherichia coli secretion of an active chimeric antibody fragment. Science. 240:1988;1041-1043.
5. Bird R.E., Hardman K.D., Jacobson J.W., Johnson S., Kaufman B.M., Lee S.M., Lee T., Pope S.H., Riordan G.S., Whitlow M. Single-chain antigen-binding proteins [published erratum appears in Science, 1989, April 28; 244(4903):409]. Science. 242:1988;423-426.
6. Reiter Y., Brinkmann U., Webber K.O., Jung S.H., Lee B., Pastan I. Engineering interchain disulfide bonds into conserved framework regions of Fv fragments: improved biochemical characteristics of recombinant immunotoxins containing disulfide-stabilized Fv. Protein Eng. 7:1994;697-704.
7. Hu S., Shively L., Raubitschek A., Sherman M., Williams L.E., Wong J.Y., Shively J.E., Wu A.M. Minibody: A novel engineered anti-carcinoembryonic antigen antibody fragment (single-chain Fv-CH3) which exhibits rapid, high-level targeting of xenografts. Cancer Res. 56:1996;3055-3061.
8. Hurle M.R., Gross M. Protein engineering techniques for antibody humanization. Curr. Opin. Biotechnol. 5:1994;428-433.
9. Le Gall F., Kipriyanov S.M., Moldenhauer G., Little M. Di-, tri- and tetrameric single chain Fv antibody fragments against human CD19: effect of valency on cell binding. FEBS Lett. 453:1999;164-168.
10. Holliger P., Prospero T., Winter G. 'Diabodies': small bivalent and bispecific antibody fragments. Proc. Natl. Acad. Sci. USA. 90:1993;6444-6448.
11. Kostelny S.A., Cole M.S., Tso J.Y. Formation of a bispecific antibody by the use of leucine zippers. J. Immunol. 148:1992;1547-1553.
12. De Jonge J., Brissinck J., Heirman C., Demanet C., Leo O., Moser M., Thielemans K. Production and characterization of bispecific single-chain antibody fragments. Mol. Immunol. 32:1995;1405-1412.
13. Cao Y., Suresh M.R. Bispecific antibodies as novel bioconjugates. Bioconjug. Chem. 9:1998;635-644.
14. Kreitman R.J. Immunotoxins in cancer therapy. Curr. Opin. Immunol. 11:1999;570-578.
15. Lode H.N., Xiang R., Becker J.C., Gillies S.D., Reisfeld R.A. Immunocytokines: a promising approach to cancer immunotherapy. Pharmacol. Ther. 80:1998;277-292.
16. Muller B.H., Chevrier D., Boulain J.C., Guesdon J.L. Recombinant single-chain Fv antibody fragment-alkaline phosphatase conjugate for one-step immunodetection in molecular hybridization. J. Immunol. Methods. 227:1999;177-185.
17. Saviranta P., Haavisto T., Rappu P., Karp M., Lovgren T. In vitro enzymatic biotinylation of recombinant fab fragments through a peptide acceptor tail. Bioconjug. Chem. 9:1998;725-735.
18. Sibler A.P., Kempf E., Glacet A., Orfanoudakis G., Bourel D., Weiss E. In vivo biotinylated recombinant antibodies: high efficiency of labelling and application to the cloning of active anti-human IgG1 Fab fragments. J. Immunol. Methods. 224:1999;129-140.
19. McCafferty J., Griffiths A.D., Winter G., Chiswell D.J. Phage antibodies: filamentous phage displaying antibody variable domains. Nature. 348:1990;552-554.
20. Scott J.K., Smith G.P. Searching for peptide ligands with an epitope library. Science. 249:1990;386-390.
21. Barbas C., Kang A.S., Lerner R.A., Benkovic S.J. Assembly of combinatorial antibody libraries on phage surfaces: the gene III site. Proc. Natl. Acad. Sci. USA. 88:1991;7978-7982.
22. Hoogenboom H.R., de ruine A.P., Hufton S.E., Hoet R.M., Arends J.W., Roovers R.C. Antibody phage display technology and its applications. Immunotechnology. 4:1998;1-20.
23. Biocca S., Pierandrei-Amaldi P., Campioni N., Cattaneo A. Intracellular immunization with cytosolic recombinant antibodies. Biotechnology. 12:1994;396-399.
24. Richardson J.H., Marasco W.A. Intracellular antibodies: development and therapeutic potential. Trends Biotechnol. 13:1995;306-310.
25. Biocca S., Neuberger M.S., Cattaneo A. Expression and targeting of intracellular antibodies in mammalian cells. EMBO J. 9:1990;101-108.
26. Proba K., Worn A., Honegger A., Pluckthun A. Antibody scFv fragments without disulfide bonds made by molecular evolution. J. Mol. Biol. 275:1998;245-253.
27. Beste G., Schmidt F.S., Stibora T., Skerra A. Small antibody-like proteins with prescribed ligand specificities derived from the lipocalin fold. Proc. Natl. Acad. Sci. USA. 96:1999;1898-1903.
28. Visintin M., Tse E., Axelson H., Rabbitts T.H., Cattaneo A. Selection of antibodies for intracellular function using a two-hybrid in vivo system. Proc. Natl. Acad. Sci. USA. 96:1999;11723-11728.
29. Lener M., Horn I.R., Cardinale A., Messina S., Nielsen U.B., Rybak S.M., Hoogenboom H.R., Cattaneo A., Biocca S. Diverting a protein from its cellular location by intracellular antibodies. The case of p21Ras. Eur. J. Biochem. 267:2000;1196-1205.
30. Biocca S., Pierandrei-Amaldi P., Cattaneo A. Intracellular expression of anti-p21ras single chain Fv fragments inhibits meiotic maturation of Xenopus oocytes. Biochem. Biophys. Res. Commun. 197:1993;422-427.
31. Cochet O., Kenigsberg M., Delumeau I., Virone-Oddos A., Multon M.C., Fridman W.H., Schweighoffer F., Teillaud J.L., Tocque B. Intracellular expression of an antibody fragment-neutralizing p21 ras promotes tumor regression. Cancer Res. 58:1998;1170-1176.
32. Caron de Fromentel C., Gruel N., Venot C., Debussche L., Conseiller E., Dureuil C., Teillaud J.L., Tocque B., Bracco L. Restoration of transcriptional activity of p53 mutants in human tumour cells by intracellular expression of anti-p53 single chain Fv fragments. Oncogene. 18:1999;551-557.
33. Deshane J., Grim J., Loechel S., Siegal G.P., Alvarez R.D., Curiel D.T. Intracellular antibody against erbB-2 mediates targeted tumor cell eradication by apoptosis. Cancer Gene Ther. 3:1996;89-98.
34. Beerli R.R., Wels W., Hynes N.E. Intracellular expression of single chain antibodies reverts ErbB-2 transformation. J. Biol. Chem. 269:1994;23931-23936.
35. Richardson J.H., Hofmann W., Sodroski J.G., Marasco W.A. Intrabody-mediated knockout of the high-affinity IL-2 receptor in primary human T cells using a bicistronic lentivirus vector. Gene Ther. 5:1998;635-644.
36. Vanhove B., Charreau B., Cassard A., Pourcel C., Soulillou J.P. Intracellular expression in pig cells of anti-α-1,3-galactosyltransferase single-chain FV antibodies reduces Gal α1, 3Gal expression and inhibits cytotoxicity mediated by anti-Gal xenoantibodies. Transplantation. 66:1998;1477-1485.
37. Chames P., Fieschi J., Baty D., Duche D. Intracellular immunization of prokaryotic cells against a bacteriotoxin. J. Bacteriol. 180:1998;514-518.
38. Tavladoraki P., Benvenuto E., Trinca S., De Martinis D., Cattaneo A., Galeffi P. Transgenic plants expressing a functional single-chain Fv antibody are specifically protected from virus attack. Nature. 366:1993;469-472.
39. Rondon I.J., Marasco W.A. Intracellular antibodies (intrabodies) for gene therapy of infectious diseases. Annu. Rev. Microbiol. 51:1997;257-283.
40. Chen J.D., Yang Q., Yang A.G., Marasco W.A., Chen S.Y. Intra- and extracellular immunization against HIV-1 infection with lymphocytes transduced with an AAV vector expressing a human anti-gp120 antibody. Hum. Gene Ther. 7:1996;1515-1525.
41. Mhashilkar A.M., Bagley J., Chen S.Y., Szilvay A.M., Helland D.G., Marasco W.A. Inhibition of HIV-1 Tat-mediated LTR transactivation and HIV-1 infection by anti-Tat single chain intrabodies. EMBO J. 14:1995;1542-1551.
42. Duan L., Zhu M., Bagasra O., Pomerantz R.J. Intracellular immunization against HIV-1 infection of human T lymphocytes: utility of anti-rev single-chain variable fragments [published erratum appears in Hum. Gene Ther., 1998, March 20; 9765]. Hum. Gene Ther. 6:1995;1561-1573.
43. Steinberger P., Andris-Widhopf J., Buhler B., Torbett B.E., Barbas C.F. III. Functional deletion of the CCR5 receptor by intracellular immunization produces cells that are refractory to CCR5-dependent HIV-1 infection and cell fusion. Proc. Natl. Acad. Sci. USA. 97:2000;805-810.
44. Collier A.C., Coombs R.W., Schoenfeld D.A., Bassett R., Baruch A., Corey L. Combination therapy with zidovudine, didanosine and saquinavir. Antiviral Res. 29:1996;99.
45. Hudson P.J. Recombinant antibody constructs in cancer therapy. Curr. Opin. Immunol. 11:1999;548-557.